In Vitro Evaluation of Antiprotozoal and Antiviral Activities of Extracts from Argentinean Mikania Species

The aim of this study was to investigate the antiprotozoal and antiviral activities of four Argentinean Mikania species. The organic and aqueous extracts of Mikania micrantha, M. parodii, M. periplocifolia, and M. cordifolia were tested on Trypanosoma cruzi epimastigotes, Leishmania braziliensis promastigotes, and dengue virus type 2. The organic extract of M. micrantha was the most active against T. cruzi and L. braziliensis exhibiting a growth inhibition of 77.6 ± 4.5% and 84.9 ± 6.1%, respectively, at a concentration of 10 μg/ml. The bioguided fractionation of M. micrantha organic extract led to the identification of two active fractions. The chromatographic profile and infrared analysis of these fractions revealed the presence of sesquiterpene lactones. None of the tested extracts were active against dengue virus type 2.


Introduction
Neglected tropical diseases (NTDs) are a group of infectious diseases that cause significant morbidity and mortality in the developing world. American Trypanosomiasis or Chagas' disease, leishmaniasis, and dengue are considered NTDs [1]. According to the World Health Organization (WHO), there are more than 1 billion people that suffer one or more NTD, mostly concentrated in countries of Africa, Asia, and Latin America, where life conditions are linked to poverty. As a consequence, the development of new or better drugs to fight these diseases is not a priority for the pharmaceutical industry.
Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi, affects 10 million people worldwide [2], and almost 12 million people are infected with Leishmania spp. [3]. Dengue is a viral infection caused by an RNA virus and it is estimated that 50-100 million cases occur annually while approximately half of the world's population is at risk [4].
Chagas' disease, leishmaniasis, and dengue are considered to be, among others, the most common tropical diseases in Argentina [5]. Between 1.5 and 2 million people are reported to be affected by Chagas' disease in this country [6]. American tegumentary leishmaniasis (ATL) is endemic in Northern Argentina where it is frequently associated with Chagas' disease [7] and its incidence, due in particular to Leishmania braziliensis, has increased during the last two decades [8]. On the other hand, a dengue epidemic outbreak in 2009 produced more than 25000 cases [9]. The drugs currently available to treat acute Chagas' disease infection are the nitroaromatic compounds, benznidazole and nifurtimox, both of which were discovered in the 70s' . They are effective only in the acute phase of the disease and have serious side effects [2]. The chemotherapy of leishmaniasis is based on pentavalent antimonials, amphotericin B, miltefosine and paromomycin which all have drawbacks [10]. In the case of dengue, however, currently, there are neither licensed vaccines nor any available drug to treat this viral infection [11]. In view of this situation, there is an urgent need to find new drugs to treat these NTDs.
Natural products have played an important role in the drug discovery process, since they are generally small molecules with a wide chemical diversity and more "druglikeness" than synthetic compounds, so that they are good candidates for lead drug development [12,13].
In the last decades, the Asteraceae family has been extensively studied due to the great number and variety of active compounds isolated from species belonging to it. Among these, the genus Mikania, which comprises nearly 450 species [14], has been reported to contain some interesting chemical substances, mostly terpenoid compounds (sesquiterpene lactones and diterpenes) and flavonoids. These secondary metabolites are known to have important biological activities, including anti-infective properties [15][16][17][18]. There are no previous reports concerning the evaluation of Mikania spp. on dengue virus, though M. micrantha has been reported to be effective against respiratory viruses [19].
The aim of the present study, thus, was to determine the in vitro antiprotozoal and antiviral activities of four Argentinean Mikania species. Organic and aqueous extracts of Mikania micrantha, M. periplocifolia, M. parodii, and M. cordifolia were tested against Trypanosoma cruzi, Leishmania braziliensis, and dengue virus.

Preparation of Plant Extracts.
The aerial parts of Mikania micrantha, M. periplocifolia, M. parodii, and M. cordifolia (20 g each) were air dried and extracted with dichloromethane/methanol (1 : 1) (200 mL) at room temperature for 24 h and then vacuum filtered. The process was repeated twice and the extracts were combined and dried under vacuum. The marc was then extracted with water in the same conditions. Aqueous extracts were freeze-dried.

High Performance Liquid Chromatography Analysis
A reversed-phase column Phenomenex-C18 (2) Luna (250 mm × 4.6 mm·5 μ.) was used. Samples were eluted with a gradient of water (A) and acetonitrile (B) from 0% B to 75% B in 30 min and 75% B to 100% B in 2 min. The flow rate was 1.0 mL/min and the separation was done at room temperature. Chromatograms were recorded and processed using the Varian Star Chromatography Workstation version 6.x.
Fractions 3 and 4 were dissolved in methanol and water (90 : 10) to a final concentration of 5 mg/mL.
Water employed to prepare the mobile phase was of ultrapure quality (Milliq). Acetonitrile (HPLC) J. T. Baker and methanol (HPLC) J. T. Baker were used.

Infrared Spectroscopic Analysis.
The IR-spectra of the active fractions 3 and 4 were recorded on FT-IR spectrophotometer (Bruker IFS-25) in chloroform solution.

Trypanocidal and Leishmanicidal Activity Assay.
Growth inhibition of T. cruzi epimastigotes and L. braziliensis promastigotes was evaluated using the previously described [ 3 H] thymidine uptake assay [15]. Parasites were adjusted to a cell density of 1. The cytotoxic concentration 50% (CC 50 ), defined as the concentration that inhibits the proliferation of exponentially growing cells by 50%, was calculated for organic and aqueous extracts.
Two-fold serial dilutions of organic (12-0.75 μg/mL) and aqueous extracts (500-31.25 μg/mL) of Mikania species were tested in quadruplicate. Mock-infected cells with and without extracts and infected cells without extract were included as controls. Ribavirin (100-1 μg/mL; Sigma-Aldrich) was used as a positive control. The CPE was determined by the measurement of cell viability using the MTS/PMS method (CellTiter 96 Aqueous) (Promega, Madison, WI) as previously described [20]. All extracts were tested at concentrations below their CC 50 .

Statistical Analysis.
The results are expressed as mean ± SEM. The level of statistical significance was determined submitting the data to one-way analysis of variance (ANOVA) using GraphPad Prism 3.0 software (GraphPad Software Inc., San Diego, CA). All data were referred to the control group. P values of <0.05 were considered significant.

Trypanocidal Activity.
The trypanocidal activity of organic and aqueous extracts of Mikania species was evaluated in vitro on T. cruzi epimastigotes. Results are presented in Table 1.
The organic extracts of the four Mikania species were found to be active against T. cruzi epimastigotes with an inhibition above 85% at 100 μg/mL. The organic extract of M. micrantha proved to be the most active of all tested species, showing an inhibition of 77.6 ± 4.5% and 14.2 ± 4.6%, when applied at concentrations of 10 and 1 μg/mL, respectively. The aqueous extracts of the four Mikania species showed inhibitions ranged between 13 and 40% at 100 μg/mL (Table 1).
According to these results, the organic extract of M. micrantha was selected for further fractionation.

Leishmanicidal Activity.
The leishmanicidal effect of extracts of Mikania species was evaluated on L. braziliensis promastigotes. The results are shown in Table 2. Aqueous extracts displayed inhibition rates below 30% at a concentration of 10 μg/mL.

Antiviral Activity.
None of the organic and aqueous extracts from the four tested Mikania species was able to inhibit the replication of DENV-2. Approximately 30% reduction of the CPE effect was observed when infected cells were treated with 500 μg/mL aqueous extracts.
At the lowest tested concentration (10 μg/mL), fractions 3 and 4 were the most active against T. cruzi with inhibition rates of 85.7 ± 7.6% and 83.4 ± 2.8%, respectively (Figure 1). The analysis of the HPLC profile of these two fractions showed the presence of the same three major peaks with retention times of 16.5, 19.2, and 20.6 min and UV maximum at 219, 217, and 223 nm, respectively ( Figure 2).The infrared spectroscopic analysis of these fractions showed the presence of bands between 1750-1790 cm −1 , corresponding to γ-lactone carbonyl group (data not shown).

Discussion
In the present study, the antiprotozoal and antiviral effects of extracts of four Argentinean Mikania species against Trypanosoma cruzi, Leishmania braziliensis, and dengue virus type 2 were evaluated.

4
The Scientific World Journal   The organic extracts of M. micrantha, M. periplocifolia, M. parodii, and M. cordifolia showed significant in vitro antiprotozoal activity against T. cruzi epimastigotes and L. braziliensis promastigotes. The M. micrantha organic extract was the most active against the two protozoans. All aqueous extracts displayed moderate to low activity against T. cruzi and L. braziliensis. This is the first time that trypanocidal and leishmanicidal activities of M. parodii are reported.
In the case of antiviral activity, neither the organic nor the aqueous extracts were able to inhibit the replication of dengue virus type 2 under the described experimental conditions.
Previous reports on the chemical composition of species of the genus Mikania (Asteraceae) describe terpenoid compounds and flavonoids as the main constituents [21][22][23][24].
There are some references about the antiprotozoal and antiviral activities of Mikania spp. [19,25,26] and particularly, in the case of the four studied species, there are some reports of studies performed on different strains, stages, and parasite species than the ones used herein [27][28][29].
The bioguided fractionation of M. micrantha organic extract resulted in the identification of the most active fractions (3,4) against T. cruzi. The chromatographic profile of these fractions revealed the presence of three major peaks with UV spectra that could be attributed to terpenoid compounds. Besides, in the infrared spectrum of these fractions, characteristic bands of sesquiterpene lactones could be observed. Thus, the active fractions 3 and 4 contain sesquiterpene lactones.
Terpenoids, mainly sesquiterpene lactones and diterpenes, are characteristic constituents of the genus Mikania and some of these metabolites have shown trypanocidal activity [24]. Thus, the trypanocidal activity of fractions 3 and 4 could be due to the presence of sesquiterpene lactones, since some of these compounds have been previously reported in M. micrantha [30][31][32].
These findings reveal the importance of the Mikania genus as a rich source of antiprotozoal molecules. Isolation and purification of the bioactive compounds from the active fractions of M. micrantha and bioassay-guided fractionation of the other active extracts are under way.